Screener
Vaxcyte, Inc. PCVX Restricted Cash
Restricted Cash at other companies
Other financials
Where this comes from
Reported directly by Vaxcyte, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RestrictedCash.
The source filing: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 4:12 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001649094-26-000017
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Cash, cash equivalents and restricted cash, beginning of period | 175,425 | 389,195 |
| Cash, cash equivalents and restricted cash, end of period | $262,309 | $348,169 |
| Reconciliation of cash, cash equivalents and restricted cash: | ||
| Cash and cash equivalents | $260,843 | $346,850 |
| Restricted cash | 1,466 | 1,319 |
| Cash, cash equivalents and restricted cash | $262,309 | $348,169 |
| Supplemental disclosure of non-cash investing and financing activities: | ||
| Purchases of property and equipment recorded in accounts payable and accrued expenses | $6,343 | $3,889 |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Vaxcyte, Inc.'s restricted cash?
- Vaxcyte, Inc. (PCVX) reported restricted cash of $1.47M in Q1 2026.
- How has Vaxcyte, Inc.'s restricted cash changed year-over-year?
- Vaxcyte, Inc.'s restricted cash increased by 11.1% year-over-year, from $1.32M to $1.47M.
- What is the long-term trend for Vaxcyte, Inc.'s restricted cash?
- Over 4 years (2021 to 2025), Vaxcyte, Inc.'s restricted cash has grown at a 13.9% compound annual growth rate (CAGR), from $871K to $1.47M.
- What does restricted cash mean?
- Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.
Ask your AI about Vaxcyte, Inc.'s restricted cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude